Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.82 +1.04%
Financial Fact:
Earnings per basic share: -0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Earnings per basic share: -0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.
GUIDANCE:
Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Goldcana closes $1M private placement of flow-through shares
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
